Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
By chance the investigators found that iv. silibinin has a potent antiviral effect against
the hepatitis C virus. Based on the results of the dose finding study (published) te optima
dosing schedule is explored.This study will be evaluate whether the highest active dose given
for the optimal time combined with standard of care will result in a sustained virologic
response (=cure of hepatitis C).